Phaseline

Targets › IDH2

IDH2 (Isocitrate dehydrogenase [NADP], mitochondrial): drug programs, companies and trials

7 programs from 7 companies in 31 trials: 13 Phase 1, 12 Phase 2, 6 Phase 3; Oncology, Hematology, Gastroenterology; next expected readout Nov 2026.

Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), playing a role in intermediary metabolism and energy production. Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to R-2-hydroxyglutarate. (UniProt, P48735)

Open in Phaseline: the race on IDH2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HutchmedHMPL-306
IDH1/IDH2 inhibitor
IDH1, IDH2Phase 3Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 MutationsDec 2026
ServierVorasidenib (S095032)
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 3Residual or Recurrent Grade 2 IDH Mutant GliomaOct 2030
Institut de Recherches Internationales Servier (I.R.I.S.)Vorasidenib
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 2Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 …Nov 2026
M.D. Anderson Cancer CenterEnasidenib Mesylate
Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
IDH2Phase 2Acute Myeloid Leukemia; Acute Bilineal LeukemiaDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQB3455 tablet
IDH2 mutant enzyme inhibitor
IDH2Phase 1Acute Myeloid Leukemia (AML)Dec 2026
Eli LillyLY3410738
Covalent isocitrate dehydrogenase (IDH) inhibitor
IDH1, IDH2Phase 1Acute Myeloid Leukemia (AML); CholangiocarcinomaMay 2027
Bristol-Myers SquibbEnasidenib (AG-221)
Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
IDH2Phase 1Leukemia, Myeloid, Acute; Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Myelodysplastic Syndromes …–

Conditions

Acute Myeloid Leukemia (7) Acute Myeloid Leukemia (AML) (3) Cholangiocarcinoma (1) Leukemia, Myeloid, Acute (1) Recurrent Acute Myeloid Leukemia (1) Myelodysplastic Syndromes (1) Myelodysplastic Syndrome (1) T-cell Lymphoma (1) Metastatic Chondrosarcoma (1) Clonal Cytopenia of Undetermined Significance (1) Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1) Newly Diagnosed Acute Myeloid Leukemia (AML) (1)

Modalities

small molecule (7)

Companies

Eli Lilly (1) Bristol-Myers Squibb (1) Servier (1) M.D. Anderson Cancer Center (1) Hutchmed (1) Institut de Recherches Internationales Servier (I.R.I.S.) (1) Chia Tai Tianqing Pharmaceutical Group (1)

Related targets

IDH1 (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.